Literature DB >> 26178294

Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index.

Beomseok Suh1, Jae Moon Yun1, Sehhoon Park2, Dong Wook Shin1,3, Tae Hoon Lee4, Hyung-Kook Yang5, Eunmi Ahn1, Hyejin Lee1,3, Jin Ho Park1, BeLong Cho1,3.   

Abstract

BACKGROUND: Although heavy alcoholics are at heightened risk for hepatocellular carcinoma (HCC), there are no guidelines that recommend HCC screening for heavy alcoholics. This study investigated FIB-4, a noninvasive and easily applicable liver fibrosis index, as a risk factor for HCC incidence among alcohol drinkers without viral hepatitis.
METHODS: This retrospective cohort study included 6661 generally healthy adults who were 30 years old or older, did not have chronic viral hepatitis, and visited Seoul National University Hospital for a general, routine health evaluation. The future HCC incidence was determined from National Health Insurance medical service claims data (median follow-up, 6.2 years).
RESULTS: With adjustments for age, sex, body mass index, smoking, and alcohol, compared with subjects with FIB-4 values less 1.00, subjects with FIB-4 values greater than or equal to 1.75 and less than 2.10 and subjects with FIB-4 values greater than or equal to 2.10 had adjusted hazard ratios (aHRs) of 5.18 (95% confidence interval [CI], 1.12-24.00) and 13.63 (95% CI, 3.77-49.33), respectively, for HCC incidence. This was heightened in subjects who drank more 30 g of alcohol per day: the aHRs were 8.39 (95% CI, 1.28-54.87) and 16.58 (95% CI, 3.87-71.04), respectively. FIB-4 was shown to have a higher predictive value for HCC incidence than ultrasonographically detected liver cirrhosis (C-index, 0.665 vs 0.527; P = .044).
CONCLUSIONS: High FIB-4 is a risk factor with a high predictive value for HCC incidence, especially among moderate to heavy alcoholics (>30 g/d). FIB-4 is a readily available and probably cost-effective clinical tool with potential value for identifying subpopulations of alcoholics at particularly high risk who would benefit from regular HCC screening. Further investigations are warranted to validate our results; nonetheless, our study suggests that FIB-4 may be useful in HCC screening among alcoholics.
© 2015 American Cancer Society.

Entities:  

Keywords:  alcohol drinking; cancer screening; hepatocellular carcinoma; liver cirrhosis; liver fibrosis index

Mesh:

Year:  2015        PMID: 26178294     DOI: 10.1002/cncr.29577

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Infection with hepatitis viruses, FIB-4 index and risk of hepatocellular carcinoma in southern Italy: a population-based cohort study.

Authors:  Mario Fusco; Pierluca Piselli; Saverio Virdone; Pietro Di Cicco; Paola Scognamiglio; Paolo De Paoli; Valerio Ciullo; Diana Verdirosi; Michele D'Orazio; Luigino Dal Maso; Enrico Girardi; Silvia Franceschi; Diego Serraino
Journal:  Infect Agent Cancer       Date:  2016-11-03       Impact factor: 2.965

Review 2.  Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma.

Authors:  Cheng Zhang; Jinyun Li; Tao Huang; Shiwei Duan; Dongjun Dai; Danjie Jiang; Xinbing Sui; Da Li; Yidan Chen; Fei Ding; Changxin Huang; Gongying Chen; Kaifeng Wang
Journal:  Oncotarget       Date:  2016-12-06

3.  Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients.

Authors:  Xu Li; Hongqin Xu; Pujun Gao
Journal:  Med Sci Monit       Date:  2019-09-27

Review 4.  Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.

Authors:  Eirini Martinou; Marinos Pericleous; Irena Stefanova; Vasha Kaur; Angeliki M Angelidi
Journal:  Diagnostics (Basel)       Date:  2022-02-04

Review 5.  Non-invasive tests for the prediction of primary hepatocellular carcinoma.

Authors:  Giovanni Marasco; Antonio Colecchia; Giovanni Silva; Benedetta Rossini; Leonardo Henry Eusebi; Federico Ravaioli; Elton Dajti; Luigina Vanessa Alemanni; Luigi Colecchia; Matteo Renzulli; Rita Golfieri; Davide Festi
Journal:  World J Gastroenterol       Date:  2020-06-28       Impact factor: 5.742

6.  Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals.

Authors:  Francesca Faillaci; Luca Marzi; Rosina Critelli; Fabiola Milosa; Filippo Schepis; Elena Turola; Silvia Andreani; Gabriele Vandelli; Veronica Bernabucci; Barbara Lei; Federica D'Ambrosio; Laura Bristot; Luisa Cavalletto; Liliana Chemello; Pamela Sighinolfi; Paola Manni; Antonino Maiorana; Cristian Caporali; Marcello Bianchini; Maria Marsico; Laura Turco; Nicola de Maria; Mariagrazia Del Buono; Paola Todesca; Luca di Lena; Dante Romagnoli; Paolo Magistri; Fabrizio di Benedetto; Savino Bruno; Gloria Taliani; Gianluigi Giannelli; Maria-Luz Martinez-Chantar; Erica Villa
Journal:  Hepatology       Date:  2018-09       Impact factor: 17.425

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.